Bristol-Myers Squibb Company (BMY) announced today that Celgene Corporation (CELG), in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen (AMGN) under which Amgen would acquire the global rights to OTEZLA® (apremilast) for $13.4 billion in cash. Bristol-Myers Squibb previously announced the decision to divest OTEZLA in connection with the ongoing regulatory approval process for the Company’s pending merger with Celgene.

source https://finance.yahoo.com/news/bristol-myers-squibb-announces-agreement-103000117.html?.tsrc=rss